94. 原発性硬化性胆管炎 Primary sclerosing cholangitis Clinical trials / Disease details

臨床試験数 : 142 / 薬物数 : 113 - (DrugBank : 37) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 139

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-002205-38-IT (EUCTR)	02/12/2015	12/02/2018	A Study of Obeticholic Acid (OCA) in Patients with Primary Sclerosing Cholangitis	A Phase 2, Randomized, Double-Blind, Placebo-Controlled,Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects with Primary Sclerosing Cholangitis - AESOP (Assessment of Efficacy and Safety of OCA in PSC)	Primary Sclerosing Cholangitis MedDRA version: 20.0;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: OCA 1,5 mg Product Code: INT-747, OCA INN or Proposed INN: ACIDO OBETICOLICO Other descriptive name: ACIDO OBETICOLICO Product Name: OCA 5 mg Product Code: INT-747, OCA INN or Proposed INN: ACIDO OBETICOLICO Other descriptive name: ACIDO OBETICOLICO	INTERCEPT PHARMACEUTICALS INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	75	Phase 2	United States;Italy
2	NCT02177136 (ClinicalTrials.gov)	February 9, 2015	26/6/2014	Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis	Primary Sclerosing Cholangitis (PSC)	Drug: OCA;Drug: Placebo	Intercept Pharmaceuticals	NULL	Completed	18 Years	75 Years	All	77	Phase 2	United States;Italy;Austria;Belgium;France;Germany;Netherlands;Norway;Sweden;United Kingdom